Gestalt, a leading innovator in AI-powered digital pathology solutions, has raised $7.5 million Series A financing to further develop its AI-powered pathology platform, PathFlow.
This new funding will facilitate broader market adoption and increased profitability. The capital will be used to expand the company's customer base, enhance AI capabilities, and pursue FDA clearance.
The round was led by Cowles Ventures, TVF Funds, Inland Imaging Investments, KickStart Funds, and prominent angel investors from the Pacific Northwest.
Gestalt's PathFlow platform is used by leading healthcare, academic medical centres, and research organisations. Customers implement PathFlow as their preferred solution because it integrates seamlessly into their existing laboratory information systems, enabling faster, more accurate diagnoses and improving access to expert consultation, education, and research - regardless of location.
"PathFlow is transforming pathology by leveraging robust digital workflows and AI algorithms to support scoring of key biomarkers. This enables organizations to accurately match patients to known therapies and generate rich datasets for research and new drug development," said Dan Roark, CEO, Gestalt. "Our technology is designed to improve patient outcomes by enabling faster, more accurate diagnoses and broadening access to clinical expertise."
"We are incredibly grateful for the continued support from our investors," Roark added. "This funding allows us to expand on the solid foundation we've built. We've already streamlined how pathologists navigate fragmented systems by creating PathFlow, a unified platform for viewing pathology cases digitally and collaborating with leading experts in real-time without the need to ship specimens. Now, we'll accelerate innovation and scale our reach to meet the growing demands of modern pathology."
The company's platform not only improves diagnostic speed and precision which is critical for cancer patients who can wait for days to weeks or more for a diagnosis, but also unlocks AI-powered insights that enable:
- Biomarker scoring to support the optimisation of patient-therapy matching
- Image and data analysis for disease progression studies
- Interoperability enabling pathologists access to valuable aides and insights that streamline workflows, highlight areas of positivity and reduce missed diagnoses.